

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 01195/3 US	
In Re Application Of: Claude R. Jones, et al.				
Serial No. 10/609,023	Filing Date June 27, 2003	Examiner TBA	Group Art Unit TBA	
Title: Methods and Contrast Agents Useful in Quantifying Nitric Oxide				
<p>Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;"><b>OR</b></p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>				


02/05/2004 HALI11 00000071 191025 10609023

01 FC 1806 180.00 DA

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
01195/3 US

In Re Application: Claude R. Jones, et al.



Serial No.

10/609,023

Filing Date

June 27, 2003

Examiner

TBA

Group Art Unit

TBA

Methods and Contrast Agents Useful in Quantifying Nitric Oxide

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1025 as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:


\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on 01/29/04 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Signature of Person Mailing Correspondence

Keiana N. Hall

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.


  
Signature

Dated: January 29, 2004

Philip B. Polster, II  
Reg. No. 43,864

Customer No. 26648

cc:



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (10-03)  
Approved for use through 07/31/2006. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) \$180.00

## Complete if Known

Application Number	10/609,023
Filing Date	June 27, 2003
First Named Inventor	Claude R. Jones
Examiner Name	TBA
Art Unit	TBA
Attorney Docket No.	01195/3

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit  
Account  
Number

19-1025

Deposit  
Account  
Name

Pharmacia Corporation

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☐ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$)

### 2. EXTRA CLAIM FEES FOR UTILITY AND

Extra Claims		Fee from below	Fee Paid
Total Claims	-20** =		
	0	X	0.00
Independent Claims	-3** =		
	0	X	0.00
Multiple Dependent			

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	18	2202	9	Claims in excess of 20	
1201	86	2201	43	Independent claims in excess of 3	
1203	290	2203	145	Multiple dependent claim, if not paid	
1204	86	2204	43	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$) \$0.00

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non - English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR § 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Statement	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	
Other fee (specify)					

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) \$180.00

## SUBMITTED BY

Name (Print/Type)

Philip B. Polster, II

Registration No.  
(Attorney/Agent)

43,864

Complete (if applicable)

Telephone

314-274-9094

Signature

*Philip B. Polster, II*


Date

January 29, 2004

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



<b>CERTIFICATE OF MAILING "FIRST CLASS MAIL"</b> Applicant: Claude R. Jones, et al.			Docket No. 01195/3 US
Serial No. 10/609,023	Filing Date June 27, 2003	Examiner TBA	Group Art Unit TBA
Invention: Methods and contrast Agents Useful in Quantifying Nitric Oxide			
I hereby certify that the following correspondence: Fee Transmittal, Form 1449, Copy of Cited References, Transmittal of Information Disclosure Statement, and Postcard			
(identify type of correspondences)			
is being deposited with the United States Postal Service "First Class Mail Post Office to Addressee" service under 37 CFR 1.8 in an envelope addressed to: The Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on <u>January 29, 2004</u> (Date)			
<u>Keianaa N. Hall</u> (Type or Printed Name of Person Mailing Correspondence)			
<u>Keianaa Hall</u> (Signature of Person Mailing Correspondence)			



<b>FORM PTO-1449</b> U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>ATTY. DOCKET NO.:</b> 01195/3	<b>APPLICATION NO.:</b> 10/609,023
	<b>INVENTOR</b> Claude Jones, et al.	
	<b>Filed:</b> June 27, 2003	<b>Group:</b>

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	6 4 0 7 1 3 5	June 18, 2002	Lai et al.	514	423	Dec. 3, 1999

**OTHER DOCUMENTS**

Examiner Initial	Seq	Author	Title, Publication, Relevant Pages, Date and Place of Publication
	2	L. Berliner et al.	Unique in Vivo Application of Spin Traps (Unconventional Use of Spin Trapping with ESR and NMR); Free Radical Biology & Medicine 30/5:489-499 (2001)
	3	S. Decatur et al.	Trans Effects in Nitric Oxide Binding to Myoglobin Cavity Mutant H93G; Biochemistry 35:4939-4944 (1996)
	4	F. Di Salle et al.	Nitric Oxide-Haemoglobin interaction: A new Biochemical Hypothesis for Signal changes in fMRI; NeuroReport 8: 461-464 (1997)
	5	H. Fujii, et al.	In Vivo Imaging of Apin-Trapped Nitric Oxide in Rats With Septic Shock: MRI Spin Trapping; Magnetic Resonance in Medicine 42:235-239 (1999)
	6	S. Pou et al.	Spin Trapping of Nitric Oxide by Ferro-Chelates: Kinetic and In Vivo Pharmacokinetic Studies; Biochimica et Biophysica Acta 1427:216-226 (1999)
	7	M.R. Thomas et al.	<sup>19</sup> F NMR of Trifluoroacetyl-Labeled Cysteine Mutants of Myoglobin: Structural Probes of Nitric Oxide Bound to the H93G Cavity Mutant; Biochemistry 40:8588-8596 (2001)

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	